Neil William Aubuchon
Known title: Chief Commercial OfficerCIK: 0002106781
Neil William Aubuchon's purchase track record
Neil William Aubuchon has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/10/2026 | VKTX | $150K | -15.7% | -2.8% | +13.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| VKTX | ▲ Buy | Open Market | 4,475 | $150K | 3/10/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Viking Therapeutics Launches New Oral Obesity Study
Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.
Viking Therapeutics Launches New Oral Obesity Study. Viking Therapeutics announced a new oral maintenance study for its obesity program, a key step in its drug development pipeline. This news comes as the stock has fallen over 30% in the last three months, trading near its 52-week low. While an analyst recently maintained a buy rating with a lowered price target, the broader market view remains mixed given the recent price decline.